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It  is  now  well  established  that,  under  certain  conditions,  the  macrophage  can 
display effector cell function toward a variety of neoplastic cells (1-5). This process is 
facilitated by a series of reactions that alter the functional state of the macrophage to 
produce an activated mononuclear phagocyte (6-8). Current evidence indicates that 
activation  is  initiated  and/or  augmented  by a  nonspecific T  cell  product  denoted 
macrophage-activating factor  (MAF)  (9-13). 1 MAF  has been shown  to  develop  in 
vitro after the interaction of immune T lymphocytes with antigen-pulsed macrophages 
or mitogen stimulation  of normal splenic cell suspensions and  is thought  to alter a 
number of functional and biochemical properties of macrophages (reviewed in  14). 
The biochemical identity of MAF, and therefore the elucidation of its mechanism 
of action  on  macrophage populations,  have remained  ill-defined.  In part,  this  has 
been due to the limited amounts of MAF produced under conventional conditions, 
amounts  insufficient  to  achieve  a  full  biochemical  purification  of  this  factor.  In 
addition,  because  conventional  culture  supernatants  of activated  T  cells  normally 
contain a heterogeneous mixture of lymphokines that can affect macrophage function 
such  as immune interferon  (IFNv) and  migration-inhibition  factor, uncertainty  has 
arisen  as  to  the  chemical  identity  of MAF.  Herein,  MAF  will  be  defined  by  its 
function in inducing macrophage cytocidal activity toward neoplastic cells. 
To  circumvent  this  problem, we  initiated  a  series of experiments  to  test  several 
existing murine T  cell hybridomas for their ability to produce MAF. These cell lines 
had been constructed by fusion of alloantigen-activated T  cell blasts with the BW5147 
T  lymphoma cell  line  and  were  previously  found  to  produce  other  lymphokines, 
including allogenic effect factor (15)  and interleukin 2 (IL-2) (16).  The present study 
documents the identification of a T  cell hybridoma that secretes large quantities of a 
biologically active  factor that  is  functionally  and  biochemically  identical  to  MAF 
produced by conventional technique. The identification of this clone should prove to 
be invaluable in the ultimate purification of MAF. 
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Materials  and Methods 
Media, Supplements, and Buffers.  All media, supplements, and buffers used in these experiments 
were prepared from endotoxin-free stocks and were determined to be free of endotoxin using 
the  Limulus  Ameboeyte  Lysate  assay  (Sigma  Chemical  Co.,  St.  Louis,  MO).  To  destroy 
endotoxin that  might have potentially been adherent  to glass,  all  autoclaved glassware was 
baked for 3 h at  180°C.  RPMI  1640 and minimal essential  medium (MEM)  were prepared 
from powdered medium (Flow Laboratories, Rockville, MD) using USP sterile water (Travenol 
Laboratories, Inc., Deerfieid, IL). Liquid Dulbecco's modified Eagle medium containing 4,500 
mg glucose/liter  (DME)  was purchased  from Irvine Scientific  (Santa Ana, CA). Aseptically 
drawn fetal calf serum (FCS)  (Rehatuin F.S.) was obtained from Reheis Chemical Co., Phoenix, 
AZ and heat inactivated (1 h, 56°C) before use. Other media supplements included: injectable 
penicillin G and streptomycin sulfate (Eli Lilly and Co., Indianapolis, IN), injectable sodium 
bicarbonate  and  sodium  heparin  (Gibco Invenex Div.,  Lawrence, MA),  1 M  Hepes buffer 
solution, versene,  sodium pyruvate, and L-glutamine (M.  A. Bioproducts, Walkersville, Md.), 
10 mM MEM nonessential amino acids, and Trypsin-EDTA (1X)  (Gibeo Laboratories, Grand 
Island  Biological  Co.  Grand  Island,  NY),  gentamycin  (Sehering  Corp.,  Kenilworth,  N  J), 
Indomethacin (Sigma Chemical Co.), and concanavalin A (Con A) (Miles-Yeda, Ltd., Rehovot, 
Israel). 
Mice.  C3H/St and (BALB/c ×  DBA/2) Fl hybrid mice were obtained from the breeding 
colony at the Research Institute of Scripps Clinic. A/St mice were obtained from West Seneca 
Laboratories (West Seneca, NY). 
Production of Conventional MAF Supernatant.  Spleens of 25 A/St mice were removed aseptically, 
and single-cell  suspensions were prepared by passage through a Cellector Tissue Sieve (Bellco 
Glass, Inc., Vineland, N  J). The yield of cells was 1.2 ×  10  s cells per spleen and the isolated cells 
exhibited a viability of 80%. Cells were washed and suspended to a concentration of 5 ×  10e/ml 
in RPMI 1640 containing 5% FCS, penicillin (50 U/ml), streptomycin (50 pg/ml), L-glutamine 
(2 raM), Hepes buffer solution (5 mM), 5 ×  10  -5 M  2-mereaptoethanol (Calbiochem-Behring 
Corp., San Diego, CA), and 5/~g/ml Con A. The cell suspension was incubated in T150 tissue 
culture flasks  (Costar, Data Packaging, Cambridge, MA) (50 ml/flask)  for 24 h at 37°C in a 
humidified, 5% CO2 atmosphere. After incubation, the cells were removed by centrifugation at 
200 g for 15 rain and the supernatant filtered through a 0.2-pm sterilization filter unit  (Nalge 
Co., Nalgene Labware Div., Rochester, NY). The resulting supernatant  was stored frozen at 
-20"C and will heretofore be referred to as conventional MAF. 
Construction and Cloning of Murine  T Cell Hybridomas.  T  cell hybridomas were constructed by 
fusion of alloactivated T cell blasts with the BW5147 T lymphoma line as described previously 
(15). Hybridomas were grown in DME containing 10% FCS, penicillin (50 U/ml), streptomycin 
(50  pg/ml),  L-glutamine  (2  raM),  and  sodium  pyruvate  (1  raM)  (complete  DME)  in  a 
humidified  atmosphere  containing  10%  CO2.  Hybridomas  were  cloned  and  subcloned  as 
described (15,  16) by limiting dilution in 96-well  flat-bottomed tissue  culture plates (Costar). 
Each  well  contained  an  average  of 0.5  hybridoma  cells  and  2  ×  105  irradiated  BALB/c 
thymocytes. 
Growth and Stimulation of T  Cell Hybridoma Clones.  Selected T  cell  hybridoma clones were 
maintained  in complete DME containing 5% FCS.  The cells,  which are partially adherent, 
were grown until the density of nonadherent cells reached  1 ×  106 viable eells/ml.  10% of the 
culture was transferred, and the remaining 90% of the culture was stimulated with Con A (i0 
pg/ml final concentration). After incubation for 24 h at 37°C, the supernatant was harvested. 
Cells  were removed  by centrifugation  and  the supernatant  was sterile  filtered  as  described 
above. 
Macrophages.  C3H/St  mice were injected intraperitoneally with  1.5 ml of sterile proteose 
peptone (10% wt/vol, Difco Laboratories, Detroit, MI) 3 d before harvest. Cells were harvested 
by peritoneal  lavage using RPMI medium containing 2%  FCS, antibiotics,  L-glutamine,  10 
mM Hepes buffer, and sodium heparin  (10 U/ml).  Cells  were washed at  4°C in the above 
buffer lacking heparin (assay washing buffer) and resuspended to 1 ×  106/ml in RPMI medium 
containing  5%  FCS,  penicillin  (50  U/ml),  streptomycin  (50 ~g/ml),  L-glutamine  (2  raM), 
sodium bicarbonate  (0.075% wt/vol), and sodium pyruvate (1  mM)  (complete RPMI). The 
yield of cells  averaged  6  ×  106 peritoneal  exudate  cells  per mouse and cell  viabilities  were ROBERT  D.  SCHREIBER,  AMNON ALTMAN, AND DAVID  H.  KATZ  679 
>95%.  Approximately  80%  of the  final  cell  suspension  represented  macrophages  based  on 
histochemical, functional, and  morphological criteria.  For use in the 5XCr release tumoricidal 
assay  for MAF,  200  /LI of the suspension  (2  ×  l0  s  peritoneal  exudate  cells) was  added  into 
6.4-mm Diam, flat-bottomed wells in 96-well tissue culture plates. The plates were centrifuged 
for 10 min at 200 g and then transferred to a 37°C incubator for 2 h to allow for cell adherence. 
After the adherence step, the wells were subjected to vigorous washing to remove nonadherent 
cells. Plates were used in the assay immediately after this last step. 
Target Cells.  The  murine  mastocytoma  cell line P815  was  used  as  a  target  in  the MAF- 
dependent tumoricidal assay. P815 cells were maintained in culture as well as by weekly in vivo 
transfer through  (BALB/c ×  DBA/2)  Fa  mice. 2  ×  10  v P815 cells in 500 p,l complete RPMI 
were labeled by incubation for 1 h at 37°C with 200/~Ci of sterile 5XCr (Na2CrO4; New England 
Nuclear,  Boston,  MA).  Cells were  washed,  suspended  in  medium  to  2  ×  106  cells/ml, and 
incubated  an additional  1 h  at  37°C to eliminate the rapid  phase of 51Cr release. Cells were 
pelleted and  washed  once more with  50 ml of complete RPMI.  5XCr-labeled P815  cells were 
then suspended  to  1.5 ×  105/ml in complete RPMI for use in the assay. 
5tCr Release Tumoricidal Assay for MAF.  The  61Cr  release  tumoricidal  assay  used  in  these 
studies will be reported in detail elsewhere, but  is basically similar to that  described by Pace 
and  Russell  (17).  Briefly,  2  ×  106  peptone-elicited  maerophages  adherent  in  96-well  tissue 
culture plates  (see above) were incubated,  in triplicate, with 200 #1 of serial dilutions of MAF- 
containing supernatants  in complete RPMI medium. Because MAF represents only one of the 
two activation signals required to induce macrophage-dependent tumoricidal activity, the wells 
also contained  1 ×  106 heat-killed Listeria monocytogenes (HKLM) organisms, which were shown 
previously to act as a second or triggering signal. Reaction mixtures also contained  1 X  10 -6 M 
indomethacin  to  prevent  inhibition  of macrophage  tumoricidal  activity  by  prostaglandins. 
Control wells, which were used to determine spontaneous  release, contained the macrophage 
monolayers, HKLM, and indomethacin,  but not MAF. After incubation for 4 h  at 37°C in a 
5% CO2 atmosphere,  the macrophage  monolayer was washed  three times in complete RPMI 
medium containing  1 X  10  -6 M  indomethacin.  3 ×  104 ~lCr-labeled P815 cells in 200 #1 of the 
above medium were added to the wells (effector/target cell ratio -- 6.7:1), and cell-cell contact 
was  initiated  by  centrifugation  of  the  reaction  plate  for  10  min  at  200  g.  Cultures  were 
incubated  for  16  h  at  37°C  in  a  humidified  5%  CO2  atmosphere.  At  the  completion  of 
incubation, plates were centrifuged for 10 min at 200 g and  100-pl samples removed from each 
well. The radioactivity content of each sample was assessed  in an automatic gamma counter 
(Micromedic  Systems,  Horsham,  PA),  and  the  percent  specific SlCr release was  determined 
using  the  formula:  percent  specific release  =  100  ×  ([experimental  release  -  spontaneous 
release]/[total  release  -  spontaneous  release]).  Total  releasable  counts  were  determined  in 
quadruplicate by subjecting labeled targets to two cycles of freezing and thawing. Spontaneous 
release from 51Cr-labeled P815 averaged  1-2%/h.  1 U  of MAF is defined as that amount which 
produces 50% maximal 61Cr release in this assay. 
Interferon Assay.  Interferon was identified by its ability to protect murine L cells (clone 929) 
from  infection  by  vesicular  stomatitus  virus  (VSV)  using  the  cytopathic  effect  assay  (18). 
Purified VSV was prepared by published methods (19)  and was a gift from Dr. D. Beebe of this 
institute. Serial twofold dilutions of interferon were mixed, in triplicate, with 3 ×  104 mouse L 
cells in fiat-bottomed 96-well tissue culture plates. The total reaction volume was 200/tl  and 
the medium  was  MEM  containing  10%  FCS, gentamycin  (50 p.g/ml),  L-glutamine  (2 mM), 
sodium bicarbonate  (0.075% wt/vol), sodium pyruvate (1 mM), and MEM nonessential amino 
acids (0.1  mM). After incubation  for  18 h  at  37°C, L  cell monolayers were washed and  then 
infected  with  200  /zl of diluted,  purified  VSV.  Plates  were  read  when  control  wells,  which 
received VSV but not IFN, showed a  complete cytopathic effect (36-48 h  postinfection).  1 U 
of IFN is defined as that amount providing the L cell monolayers with 50% protection from the 
cytopathic effects of the virus. 
IL-2 Activity.  The assay for ILo2 was based upon the ability of this lymphokine to support 
the growth of the IL-2-dependent  T  cell line CTLL-2 in a  short-term  (24 h)  assay, using  1 × 
104 CTLL-2 cells and serial dilution of test supernatants,  as described (16). 
Gel Filtration Chromatography ofHybridoma MAF.  80 ml of clone 24/G 1 MAF was concentrated 
to 5 ml and applied to a  2.5 ×  100-cm column of Sephadex G 100  (Pharmacia Fine Chemicals, 680  MACROPHAGE+ACTIVATING  FACTOR  PRODUCED  BY  T  CELL  HYBRIDOMA 
Div. of Pharmacia Inc., Piscataway, N  J). The column was eluted at 25 ml/h at 4°C with a 
buffer that contained NaCI (0.25 M), Hepes buffer (0.02 M), and a-methyl-D-mannoside (0.1 
M). Samples of the fractions were diluted in medium and sterile  filtered before testing in the 
MAF assay. 
Chromatofocusing.  The pool containing the majority of the MAF activity that  had eluted 
from the Sephadex G100 column  (pool  III, fractions 37-47)  was concentrated to 6 ml and 
dialyzed against 25 mM midazole-HCl, pH 7.4. The sample was applied to a  1.0 ×  18.5-cm 
column  of Polybuffer  Exchanger  PBE-94  (Pharmacia  Fine  Chemicals),  which  had  been 
equilibrated at pH 7.4 in 25 mM imidazole-HCl buffer. The column was eluted at 4°C with 
210 ml of Polybuffer 74-HCI (Pharmacia Fine Chemicals), diluted 1:8, and adjusted to pH 4.0. 
pH values of the eluted fractions were determined using a standard pH meter (Radiometer, 
Copenhagen, Netherlands) and then adjusted to neutrality by addition of 1 M  Hepes buffer 
solution.  Samples of the fractions were diluted in medium and sterile filtered  before testing in 
the MAF assay. 
Results 
Demonstration of Secretion of MAF Activity  by  T  Cell Hybridoma 24.  Of four parental 
hybridomas tested for their ability to secrete MAF, only one (hybridoma 24) could be 
identified  as  an  MAF  producer  (Table  I).  Although  no  MAF  activity  could  be 
detected in culture supernatants from unstimulated cells, incubation of hybridoma 24 
with mitogens such as Con A or phytohemagglutinin provoked the expression of MAF 
activity in the culture fluid. MAF activity was near maximal at a dilution of 1  : 100 of 
the stimulated culture supernatant, but disappeared at a dilution of 1:500.  This level 
of MAF represents ~20-30% of the activity found in conventional MAF preparations 
(MAF  8080)  produced  by Con  A  stimulation  of normal  murine  splenic  cells.  The 
amount of MAF released from hybridoma 24 was dependent on the mitogen concen- 
tration used.  For Con A, maximal MAF release occurred using  10-20 #g/ml of the 
mitogen whereas 40 #g/ml was inhibitory. Stimulated culture supernatants of hybrid- 
oma 24 also displayed IFN antiviral activity and IL-2 activity. 
Isolation of Clone 24/G1.  Cloning of parental hybridoma 24 at an average density 
of 0.5 cells/well yielded no clones producing MAF constitutively. Fig.  1 demonstrates 
that 24 clones produced MAF when stimulated with.10 #g/ml Con A. At least seven 
of the clones (A6, C7, DI0, E3, G1, G5, and H4) produced more MAF activity than 
the conventional MAF standard (last column on far right). An additional nine clones, 
which were found to produce >200 U  MAF/ml during the original screening, have 
not  been characterized  by titration  and are therefore indicated  by the broken bars 
TABLE  I 
Demonstration of MAF Activity Secreted From T Cell Hybridoma 24 Upon Stimulation 
With Con A 
Dilution of MAF  Percent specific P815 lysis 
source  Hyb 24/Con A*  Hyb 24~:  Con A§  MAF 808011 
1:20  51.4  3.9  0.0  49.8 
1:100  43.7  N.D.  N.D.  51.1 
1:500  4.2  N.D.  N.D.  29.1 
1:2500  0.0  N.D.  N.D.  6.8 
* Culture of hybridoma 24 incubated 18 h with 10 #g/ml Con A. 
Unstimulated control of hybridoma 24. 
§ Con at  10 #g/ml incorporated in the lysis assay. 
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FiG.  1.  MAF and IL-2 production  by clones of T  cell hybridoma 24. 5-ml cultures of 27 T  cell 
clones were stimulated for 24 h  with  10 #g/ml Con A  in DME containing 5% FCS.  None of the 
clones produced  MAF constitutively, but  15 of 27  produced  IL-2 constitutively. MAF and IL-2 
activities of a  conventional MAF standard prepared  by Con A  stimulation of a  normal murine 
splenic cell culture are shown by the vertical bars on the far right. 
TABLE II 
Independent Production of MAF and IL-2 by Hybridoma 24 Clones 
Clone 
Lymphokine activity (percent of standard)* 
MAF  IL-2 
A6  175  2 
AL0  33  675 
E3  137  50 
G 1  2,500  440 
G4  4  0 
G5  800  208 
H4  800  440 
* Standard was Con Aostimulated normal spleen cell culture supernatant. 
labeled: N.T. >  200: 
Fig.  1 also quantitates the production of IL-2 by the clones. Unlike MAF, IL-2 was 
produced as  a  constitutive product by  15  out  of 27  clones,  although only in  low 
concentrations. Upon stimulation with Con A,  18 of the clones responded with IL-2 
secretion. Ten clones (AI0, C7,  D10,  El, F5, F6, F11,  G1, G5, and H4)  produced 
more IL-2 than did normal mouse splenic cells stimulated under the same conditions. 
Table  II  demonstrates  that  expression  of MAF  and  IL-2  activities  in  stimulated 
supernatants of the various clones varied independently of one another. Clone 24/A6 682  MACROPHAGE-ACTIVATING FACTOR  PRODUCED  BY  T  CELL  HYBRIDOMA 
produced  high  levels  of  MAF  but  low  amounts  of  IL-2,  whereas  clone  24/A10 
produced high concentrations of IL-2 but only minimal levels of MAF. Clones 24/G 1, 
24/G5, and 24/H4 secreted high amounts of both lymphokines, but the quantitative 
levels of the two activities varied independently of one another. 
When  cytotoxicity titrations were performed  (Fig.  2), the supernatant  from clone 
24/G1 was found to contain 55,000 U  of MAF/ml and was 23 times greater than the 
conventional  MAF  standard  (2,400  U/ml).  To  rule  out  the  possibility  that  the 
hybridoma  MAF  contained  an  enhancing  activity  or  that  the  conventional  MAF 
contained a  MAF inhibitor, hybridoma MAF and conventional MAF were mixed at 
varying ratios  and  then  titered  in  the  cytotoxicity assay.  Table III shows  that  the 
above  possibilities  are  unlikely  because  the  MAF  activity  of the  mixtures  closely 
approximated calculated theoretical values. 
Comparison of Heat and pH Sensitivities of Hybridoma MAF and Conventional MAF.  Fig. 
3 shows that the hybridoma MAF was stable to incubation for 1 h at 4°C, 37°C, and 
56°C,  but was inactivated when  held at 65°C  or 80oc  for 60 min.  Exposure of the 
preparation  to  100°C  for 20 rain  also abrogated the MAF activity. This pattern of 
heat  sensitivity  is  identical  to  that  of conventional  MAF,  but  differs  with  results 
reported elsewhere  (20)  that  MAF is inactivated after  1 h  at 56°C.  This difference, 
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Fzc.  2.  MAF titration of a Con A-stimulated supernatant of T  cell  hybridoma clone 24/G1  (O). 
The  dose-dependent  ability  of the  hybridoma MAF  to  induce  tumoricidal  activity  in  peptone- 
elicited  macrophages is compared with the activity  present  in  the  Con  A-stimulated splenic cell 
culture supernatant (C)). The latter is the conventional MAF standard used in this study. The ~lCr- 
release tumoricidal assay was performed as described in Materials and Methods. 
TABLE  III 
Mixing of Hybridoma (24/G1) and Conventional (8080) MAF Preparations: 
Lack of Enhancement or Inhibition 
MAF ratio 
24/G1:8080 
MAF Activity 
Measured  Theoretical 
U/ml 
1:0  51,200  -- 
0:1  3,200  -- 
3:1  35,800  39,200 
1:1  25,600  27,200 
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FIG.  3.  Comparison  of heat  sensitivities  of T  cell  hybridoma  MAF  and  conventional  MAF 
preparations. 5-ml samples of each MAF preparation in medium containing 5% FCS were held at 
the  designated  temperatures  for  1  h  and  then  titrated  for  MAF  activity  in  the  SlCr-release 
tumoricidal assay. 
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Flo.  4.  Comparison of pH sensitivities of T  cell hybridoma MAF and conventional MAF prepa- 
rations. 5-ml samples of each MAF-contalning supernatant were subjected to dialysis for  18 h  at 
4°C against  1 liter of physiological saline buffered to the designated pH values. Samples were then 
back dialyzed into 0.1 M phosphate buffer pH 7.4 for 4 h and then dialyzed into phosphate-buffered 
saline.  Treated  samples were  titrated  for  MAF  activity  and  the  amount  of activity  remaining 
compared to the untreated controls. 
however, is caused by the presence of FCS in our MAF preparations, as stimulation 
of hybridoma 24 with Con A in serum-free medium results in the production of MAF 
that is labile to 56°C  (64% activity lost after 1 h). 
Fig. 4 demonstrates that hybridoma MAF and conventional MAF share identical 
pH sensitivities. Treatment of both preparations at or below pH 4.0 resulted in the 
loss of 80% of the MAF activity. No loss in activity was found upon treatment at pH 
7.0 or 5.0.  Identical results were obtained when the pH of the lymphokine solutions 
was adjusted in the test tube by titration with HCI and held constant for 6 h at 4°C 
before neutralizing them with NaOH. 
Demonstation of a  Requirement for a  Second Signal  in  Induction of Macrophage Cytocidal 
Activity  by Hybridoma and Conventional MAF.  It has previously been found that the in 
vitro induction  of macrophage tumorieidal  activity requires  the  participation  of a 
second signal that is distinct from MAF (17, 21-23). A variety of substances, including 
endotoxin,  have been  found  to act  as second  signals  (reviewed in  22).  In our own 
experiments  (23),  we  have  found  that  either  heat-killed  HKLM  or endotoxin  can 684  MACROPHAGE-ACTIVATING FACTOR  PRODUCED  BY  T  CELL  HYBRIDOMA 
enhance MAF activity 50-fold in the tumoricidal assay. Table IV demonstrates that 
similar  enhancement  of  MAF  activity  by  a  second  signal  is  observed  for  both 
hybridoma MAF (42-fold) and conventional MAF (50-fold). 
Gel Filtration Chromatography of Hybridoma MAF on  Sephadex GIO0.  Conventional 
MAF has been shown to have a molecular weight of 40,000-60,000 when subjected to 
molecular  sieve  chromatography  (20,  23,  24).  A  16-fold  concentrated  sample  of 
24/G1  MAF was applied to a column of Sephadex G100 to determine the molecular 
TABLE  IV 
Demonstration  of a Requirement for a Second Signal in the Induction  of 
Macrophage  Tumoricidal  Activity by Conventional MAF and Hybridoma  MAF 
MAF activity 
MAF preparation 
Plus HKLM*  Minus HKLM 
U/ml 
Conventional MAF (8080)  1,750  35 
Hybridoma MAF (817 I)  21,420  510 
* HKLM used at  a  final concentration of 5  X  108/ml  as a  source of second 
signal. 
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FIG.  5.  Gel  filtration  chromatography of T  cell  hybridoma MAF on  Sephadex GI00. 80  ml of 
hybridoma MAF was concentrated to 5 ml by ultrafihration and applied to a 2.5 ×  100-cm column 
of Sephadex  G100  equilibrated  in  0.02  M  Hepes  buffer  containing  0.24  M  NaCI  and  0.1  M 
a-n-methyl mannoside. Elution was performed at 4°C at a flow rate of 25 ml/h. 5-ml fractions were 
collected.  Fractions were pooled as designated by the vertical vats and roman numerals. 
TABLE  V 
Recoveries of MAF Activity From Sephadex  GIO0 Column 
Column pool 
MAF activity 
Total units  Percent recovery 
I  4,110  0.4 
II  140,880  13.8 
III  413,440  40.5 
IV  21,120  2.1 
V  8,220  0.8 
I-V (Calculated)  587,770  57.6 
I-V (Measured)  479,040  47.0 
Unfractionated  1,020,000  -- ROBERT  D.  SCHREIBER,  AMNON  ALTMAN,  AND  DAVID  H.  KATZ 
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Fzc.  6.  Chromatofocusing of hybridoma MAF following gel filtration. Pool III from Fig.  5 was 
concentrated to 6 ml by ultrafiltration and dialyzed against 2 liters of 0.025  M  imidazole-HCl pH 
7.4. The sample was applied to a  1.0 x  18.5-cm column of Polybuffer Exchanger-94 and eluted at 
4°C with 210 ml of Polybuffer 74-HC1 diluted 1:8 and adjusted to pH 4.0. Fraction size was 2.5 ml. 
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weight of hybridoma MAF. The column was eluted with buffer that contained high 
salt and 0.1  M  a-methyl-D-mannoside. This buffer has been found to greatly reduce 
adsorption  of MAF  activity  onto  carbohydrate-containing  separation  media;  the 
enhanced yield of MAF in the presence of ~-methyl-D-mannoside appears to reflect 
the ability of MAF to interact with mannose residues in a lectinlike fashion. 
As shown in Fig. 5, the major amount of MAF activity eluted in a position behind 
bovine serum albumin and displayed a molecular weight of 55,000. This value agrees 
with the 50,000 tool wt determined for a  conventional MAF preparation under the 
same  conditions.  The  hybridoma  MAF  activity eluted  in  a  slightly asymmetrical 
manner with an increase in activity on the trailing side of the elution peak. A minor 
percentage (<10%) of activity was detectable in the fractions that corresponded to the 
void volume of the column. Fractions delineated by the vertical bars in Fig. 5 were 
pooled, and the resulting pools were titrated for MAF activity. Table V indicates that 
pool III (fractions 37-47) contained 40% of the MAF activity that had originally been 
applied. To test for the possibility that  the gel filtration step might have separated 
two distinct  activities, aliquots of pools I-V were combined and  titrated  for MAF 
activity. Table V  indicates  that  this  possibility  is  unlikely, as  the  measured  MAF 
content of the combined pools (479,040 U) is in agreement with the calculated MAF 
content of the five individual pools (587,770 U). In fact, the measured recovery (47%) 
is actually slightly lower than the calculated recovery (57.6%). 
Chromatofocusing of Hybridoma MAF.  The major activity-containing pool III of the 
hybridoma MAF was subjected to chromatofocusing. Fig. 6 demonstrates that MAF 
activity eluted as at least two distinct species. The major peak eluted at pH 5.45 and 
contained  60%  of the  activity. Very little  protein  was  found  in  this  region  of the 
elution profile. A leading edge of activity was observed for this predominant activity 
peak. A  second distinct peak eluted at pH 4.90 and was found to coelute with the 
major protein peak, which was subsequently found to be BSA derived from the FCS 
in the culture medium. 
Discussion 
This report constitutes the first description of a  T  cell hybridoma that secretes a 
lymphokine that  induces tumoricidal  activity in  macrophages;  as  designed  herein, 686  MACROPHAGE-ACTIVATING  FACTOR PRODUCED BY T  CELL HYBRIDOMA 
this lymphokine is MAF. 
MAF  has  been  reported to elicit or alter a  variety of biological responses  from 
macrophages, including increases in endocytic, biosynthetic, secretory, and effector 
cell functions as well as changes in membrane physiology and composition (reviewed 
in 14). The current, generally held concept is that two signals are required to generate 
tumoricidal activity in macrophages (17, 21-23). MAF is the first signal which primes 
the macrophage for "triggering" by a second signal (22).  Second signals constitute a 
heterogeneous group of substances which can either be host-derived or be of nonhost 
origin. 
The results presented in this study demonstrate that  a  murine T  cell hybridoma 
that secretes MAF has been obtained. Although not produced constitutively, mitogen 
stimulation of the hybridoma cell culture induced production of high levels of MAF; 
indeed,  in  quantities  considerably greater than  could be detected in  conventional 
MAF  preparations  generated  by .Con  A  stimulation  of normal  murine  spleen cell 
cultures. The activity secreted by the T  cell hybridoma was shown to be identical 
with  conventional MAF  by a  variety of functional and  biochemical criteria.  Both 
preparations required an additional component or "second signal" to induce tumor- 
icidal activity in peptone-elicited murine macrophages and exhibited identical heat 
and  pH  denaturation  profiles,  and  the  MAF  activities  from  both  supernatants 
displayed  identical  apparent  molecular weights  of 50-55,000  as  measured  by  gel 
permeation chromatography on Sephadex G100. 
The characteristics of molecular weight, inactivation after treatment at pH 4.0 or 
65°C,  and  the  requirement  for a  second signal  to induce macrophage tumoricidal 
activity displayed by our preparations of hybridoma-derived or conventional MAF 
are in agreement with those reported for conventional MAF by others (20, 24). The 
observation that MAF activity in our culture supernatants was stable to incubation 
for  1  h  at  56°C  appeared  to  be  at  variance  with  at  least  one  other  report  on 
conventional  MAF  (20).  However, these  disparate  results  were  reconciled by  the 
finding that the FCS used in our culture supernatants had a protective effect on the 
heat denaturation of MAF. 
The higher amount of MAF activity displayed by the T cell hybridoma supernatant 
when compared with the conventional MAF preparation represents an actual increase 
in  concentration  or  specific  activity  of the  hybridoma-secreted  lymphokine.  This 
conclusion was supported by the mixing experiments presented in Tables III and V. 
These results indicate that conventional MAF preparations do not contain inhibitors 
that could depress the expression of MAF cytocidal-inducing activity. When subjected 
to gel filtration chromatography, the hybridoma MAF eluted as a single activity peak 
and was recovered in high yield. Mixing aliquots of all the fractions from the column 
did not increase the recovery of MAF activity. These results indicate that no additional 
factor was present in the hybridoma MAF preparation that was distinct from MAF 
on the basis of molecular weight, but that was required for MAF-dependent induction 
of cytocidal activity. 
The  cloning experiments  performed in  the  study  indicated  that  distinct  T  cell 
hybridoma clones can produce different repertoires of individual lymphokines. The 
differences observed in lymphokine levels could be either qualitative or quantitative. 
Whereas supernatants of some clones contained high levels of MAF, supernatants of 
other  clones  displayed  only  limited  levels  of the  activity.  Several  clones  which ROBERT  D.  SCHREIBER,  AMNON  ALTMAN, AND  DAVID  H.  KATZ  687 
produced  MAF  in  high  concentration  produced  only  limited  quantities  of other 
lymphokines  (such  as  IL-2)  and  vice-versa. Although  MAF  was  not  secreted as  a 
constitutive product by any of the clones, IL-2 secretion by several clones could be 
detected in the absence of mitogen stimulation. 
By comparing the lymphokine titers in culture supernatants of different clones, it 
should be possible to distinguish between certain lymphokine activities. For instance, 
from past  studies  it  has remained unclear whether MAF  and  IFN are identical or 
distinct.  Certain types of IFN  (a and/~)  have been shown to activate macrophage 
tumoricidal  activity  (25,  26).  In  addition,  IFNy displays  a  molecular weight,  pH 
sensitivity, and heat stability (27) similar to MAF. Thus it would be of considerable 
interest if the two activities could be differentiated using the T  cell hybridoma clones. 
In fact, in the present study, four clones were initially identified that produced high 
levels of MAF activity and only limited amounts of IFN antiviral activity. One of 
these clones  (24/G1)  produced  no  detectable amounts  of IFN  activity despite  the 
expression of a  very high  level of MAF  activity. However, upon  expansion of this 
clone, stimulated culture supernatants  were found to contain both MAF and  IFN 
activities. Two posibilities that might explain this result are currently being explored: 
(a) the initial hybridoma clone may have produced both MAF and IFN but the IFN 
antiviral  activity was  masked  by an  unknown  inhibitory factor in  the  hybridoma 
supernatant.  Upon expansion of the clone, the gene for this factor was lost, thereby 
allowing for expression of the IFN antiviral activity. (b) Expression of MAF and IFN 
activities may differ kinetically, due either to different rates of biosynthesis or secretion 
or to different rates of degradation or interconvertability. 
To date, only one other report (28) exists documenting the production by a murine 
T  cell hybridoma of lymphokines that directly effect macrophage function. This study 
described supernatants from a T  cell hybridoma that produced inhibition of macro- 
phage migration and induced C2 and elastase synthesis or release by murine macro- 
phages. The levels of activity measured in the hybridoma supernatant were compa- 
rable to or slightly elevated above (two- to threefold) the activity levels observed in 
supernatants from Con A-stimulated spleen cell cultures. One particular clone, which 
exhibited  the  highest  titer  of C2-inducing  activity,  was  devoid  of IFN  antiviral 
activity. It is unknown whether the factor(s) that was produced by this hybridoma is 
the same as the MAF produced by our hybridoma. 
The identification of the T  cell hybridoma that produces large quantities of MAF 
constitutes the first step in providing the needed starting material for the biochemical 
purification  of this  lymphokine.  Once  purified,  MAF  can  be  characterized  with 
respect to the biological functions it elicits and the mechnism by which these effects 
are produced.  Hybridoma culture supernatants  are currently being  produced at  a 
rate of 1-2 liters/wk. Each liter contains the equivalent of the MAF activity that can 
be produced by the spleen cell cultures of 4,000 mice. Work is currently underway to 
devise a large-scale isolation procedure for the T  cell hybridoma-derived MAF. 
Summary 
A murine T  cell hybridoma, constructed by fusion of alloantigen-activated T  cells 
with the BW5147 T cell lymphoma, which produces a lymphokine capable of inducing 
tumoricidal activity in macrophages, has been identified. Lymphokine release could 
be detected only after mitogen stimulation of the T  cell hybridoma culture. Upon 688  MACROPHAGE-ACTIVATING FACTOR PRODUCED BY T  CELL HYBRIDOMA 
cloning of the parental hybridoma, 24 out of 27 clones produced tumoricidal-inducing 
activity.  Seven clones produced  more cytocidal-inducing  activity than  did  conven- 
tional  supernatants,  generated  by  concanavalin  A  stimulation  of normal  murine 
spleen  cell cultures,  whch  contained  macrophage-activating factor (MAF).  The su- 
pernatant  of hybridoma clone  24/G1  was  25  times more active than  conventional 
MAF preparations. Using supernatants from a  variety of clones, the levels of macro- 
phage-activating activity and interleukin 2 were found to vary independently of one 
another.  The  lymphokine  produced  by  hybridoma  clone  24/G1  appeared  to  be 
identical  to conventional  MAF by a  variety of criteria including:  (a)  a  requirement 
for a  second signal for induction  of tumoricidal activity in macrophages, (b)  inacti- 
vation after incubation for 1 h  at 65°C, and (c) loss of activity after treatment at pH 
4.0  but  not  at  pH  5.0.  Like conventional  MAF,  the  hybridoma  MAF  eluted  as  a 
single peak after molecular sieve chromatography on Sephadex G100 and exhibited 
an  apparent  molecular  weight  of 55,000.  Although  somewhat  heterogeneous,  the 
majority ofhybridoma 24/G1 MAF displayed an isoelectric point of 5.4 as determined 
using the chromatofocusing technique.  These results thus illustrate the usefulness of 
T  cell  hybridomas  in  distinguishing  between  various  lymphokine  activities  and 
indicate  that  the T  cell  hybridoma clone 24/G1  will  be of particular usefulness  in 
achieving the biochemical purification of substantial quantities of murine MAF. 
Note added in proof"  While  this paper was in production,  another study appeared 
that also documented the production of MAF by a murine T  cell hybridoma (Ratlif, 
T.  L.,  D.  L.  Thomasson,  R.  E.  McCool,  and  W. J.  Catalona,  1982.  Production  of 
macrophage-activation factor by a T-cell hybridoma. Cell.  Immunol.  68:311). 
The authors are grateful for the expert technical assistance of Lori Hicks, Peta-Maree Stidham, 
and Robin Weiner, which was invaluable in these studies. 
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